Cora Madsen
Get their honest, personalized take on your startup.
Sign in to pitch Cora →At a glance
- Full Name
- Cora Madsen
Background
I could not independently verify a public investor profile for Cora Madsen. Searches for the exact name, the provided email address, and the NB Capital domain did not surface a public biography, LinkedIn profile, firm team page, speaker page, investment profile, or portfolio attribution for this person.
NB Capital ApS is a biotech-focused investment firm. Its website states that NB Capital was seeded in 2001 by experienced biotech investors and a pharmaceutical company, and that it invests in public and private equity markets with a focus on pharmaceutical drug development and commercial enterprise.
The NB Capital website identifies Florian Schönharting as CEO and attributes the listed representative and past investments to Florian Schönharting and/or investment funds advised by NB Capital/Florian Schönharting. The site does not mention Cora Madsen.
Investment Thesis & Focus
- NB Capital says it focuses on “all phases of pharmaceutical drug development and commercial enterprise.”
- The firm describes its approach as using “principles of risk aversion and innovation” in public and private equity markets.
- NB Capital states that its aim is to find “truly low risk investments,” defined by the firm as low risk of losing capital, with potential upside over a 2–3 year time frame.
- The firm’s disclosed investment history spans seed investments, spin-outs, private investments, early public investments, public equity, and pro-management activist public investments.
- I found no public source describing Cora Madsen’s individual investment thesis, check size, decision process, or independent angel-investing activity.
Notable Investments
- Genmab A/S — NB Capital lists the role as co-founder; Genmab develops antibody therapeutics for cancer and autoimmune diseases.
- BioMarin Pharmaceutical Inc. — NB Capital lists the role as seed investor; BioMarin develops therapies for rare genetic diseases.
- ACADIA Pharmaceuticals Inc. — NB Capital lists the role as co-founder; ACADIA develops therapies for central nervous system disorders.
- Forward Pharma A/S — NB Capital lists the role as founder; the company focused on dimethyl fumarate for immune diseases.
- Zymenex — NB Capital lists the investment type as seed investment and lead investor; the company was acquired by Chiesi Group.
- Zealand Pharma — NB Capital lists the investment type as seed investment.
- Pharmacyclics — NB Capital lists the investment type as public equity and notes acquisition by AbbVie for $21 billion.
- Facet Biotech — NB Capital lists the role as pro-management activist public investor and notes acquisition by Abbott Laboratories for $450 million.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.